Prosonix’ generic version of GSK’s Flixotide Evohaler under review in EU
UK-based Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines “by design,” says its Marketing Authorization Application for PSX1001 has been validated and is being assessed under the decentralized procedure (DCP).
Prosonix has submitted the primary MAA under the DCP and a simultaneous duplicate MAA on behalf of US generic drugmaker Mylan (Nasdaq: MYL). The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) is the reference member state.
The MAA submission for PSX1001 leverages the European Union regulatory guideline CPMP/EW/4151/00 Rev. 1 that potentially allows the approval of generic inhaled products on the basis of in vitro only demonstration of therapeutic equivalence of the candidate to the reference product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze